1. Germline Mutations and Phenotypic Associations in Korean Patients With Pheochromocytoma and Paraganglioma: A Multicenter Study and Literature Review.
- Author
-
Jo KH, Lee J, Yoo J, Kim HS, Kim ES, Han JH, Jang YS, Yun JS, Son JW, Yoo SJ, Lee SH, Lim DJ, Kwon HS, Lee S, Moon S, and Kim M
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Genetic Association Studies, Genetic Testing, Neurofibromin 1 genetics, Phenotype, Republic of Korea, Succinate Dehydrogenase genetics, East Asian People, Adrenal Gland Neoplasms genetics, Adrenal Gland Neoplasms pathology, Adrenal Gland Neoplasms diagnosis, Germ-Line Mutation, High-Throughput Nucleotide Sequencing, Paraganglioma genetics, Paraganglioma pathology, Pheochromocytoma genetics, Pheochromocytoma pathology, Proto-Oncogene Proteins c-ret genetics, Von Hippel-Lindau Tumor Suppressor Protein genetics
- Abstract
Genetic testing is recommended for all patients with pheochromocytomas and paragangliomas (PPGL) to establish genotype-phenotype associations. We investigated germline mutations in 59 patients with PPGL at six Korean university hospitals using next-generation sequencing (NGS) targeting 38 PPGL-associated genes, including those recommended by the Korean PPGL Task Force. Germline mutations were identified in 13 patients (22%), and affected four genes: RET , NF1 , VHL , and SDHD . Germline mutations were significantly associated with a family history of PPGL, smaller tumor size, and the presence of other types of tumors. Using 95 Korean PPGL cases with germline mutations identified through a literature review and 13 cases from our cohort, we characterized genotype-phenotype correlations. Mutation hotspots were identified in specific codons of RET (codons 631 and 634), VHL (157 and 167), and SDHB (131 and 253). NF1 mutations varied, indicating the absence of common hotspots. These findings highlight the efficacy of the recommended NGS panel for Korean patients with PPGL and the importance of genetic testing in establishing clinical management and personalized therapeutic strategies.
- Published
- 2024
- Full Text
- View/download PDF